prefilled syringe

DEVICE2 trials

Sponsors

Farco-Pharma GmbH, Regeneron Pharmaceuticals

Conditions

Atopic DisordersEczema, AtopicN31.8

Phase 1

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

CompletedNCT03050151

Regeneron PharmaceuticalsAtopic Disorders, Eczema, Atopic

Start: 2017-02-28End: 2018-02-12Updated: 2018-08-01

Unknown Phase

Urodynamic and anamnestic profiles as a standardized instrument for treatment initiation and dose titration with VESOXX® - Real World study in patients with neurogenic detrusor overactivity

Active, not recruitingDRKS00028775

Farco-Pharma GmbHN31.8

Start: 2022-10-25Target: 250Updated: 2025-10-06

Related Papers

Urodynamic and Anamnestic Predictors for Individual Dose Adjustment of Intravesical Oxybutynin in Neurogenic Detrusor Overactivity: Results From the UPSIDE Study.

2026-06-22

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).

2022-05-1470 citations

Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.

2019-10-08105 citations